Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. more
Time Frame | YMAB | Sector | S&P500 |
---|---|---|---|
1-Week Return | -12.2% | -2.12% | -3% |
1-Month Return | -21.44% | -3.42% | -0.73% |
3-Month Return | -39.69% | -11.13% | 2.87% |
6-Month Return | -29.53% | -5.74% | 7.17% |
1-Year Return | 35.74% | 3.97% | 25.31% |
3-Year Return | -49.17% | 1.05% | 28.38% |
5-Year Return | -73.92% | 34.37% | 81.89% |
10-Year Return | -65.5% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 20.75M | 34.90M | 65.27M | 84.82M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":24.46,"profit":true},{"date":"2021-12-31","value":41.14,"profit":true},{"date":"2022-12-31","value":76.95,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 166.00K | 2.20M | 2.51M | 7.57M | 11.42M | [{"date":"2019-12-31","value":1.45,"profit":true},{"date":"2020-12-31","value":19.3,"profit":true},{"date":"2021-12-31","value":22.02,"profit":true},{"date":"2022-12-31","value":66.28,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (166.00K) | 18.55M | 32.38M | 57.70M | 73.40M | [{"date":"2019-12-31","value":-0.23,"profit":false},{"date":"2020-12-31","value":25.27,"profit":true},{"date":"2021-12-31","value":44.12,"profit":true},{"date":"2022-12-31","value":78.61,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | - | 89.38% | 92.80% | 88.41% | 86.54% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":96.32,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.27,"profit":true},{"date":"2023-12-31","value":93.26,"profit":true}] |
Operating Expenses | 83.00M | 138.48M | 147.82M | 152.51M | 99.08M | [{"date":"2019-12-31","value":54.42,"profit":true},{"date":"2020-12-31","value":90.8,"profit":true},{"date":"2021-12-31","value":96.92,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":64.96,"profit":true}] |
Operating Income | (83.00M) | (119.94M) | (115.43M) | (94.81M) | (25.67M) | [{"date":"2019-12-31","value":-8300400000,"profit":false},{"date":"2020-12-31","value":-11993500000,"profit":false},{"date":"2021-12-31","value":-11543300000,"profit":false},{"date":"2022-12-31","value":-9481100000,"profit":false},{"date":"2023-12-31","value":-2567200000,"profit":false}] |
Total Non-Operating Income/Expense | 3.95M | 1.20M | 58.31M | (1.51M) | 9.52M | [{"date":"2019-12-31","value":6.78,"profit":true},{"date":"2020-12-31","value":2.05,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-2.6,"profit":false},{"date":"2023-12-31","value":16.32,"profit":true}] |
Pre-Tax Income | (81.03M) | (119.34M) | (55.27M) | (95.57M) | (20.87M) | [{"date":"2019-12-31","value":-8102800000,"profit":false},{"date":"2020-12-31","value":-11933700000,"profit":false},{"date":"2021-12-31","value":-5527500000,"profit":false},{"date":"2022-12-31","value":-9556800000,"profit":false},{"date":"2023-12-31","value":-2086600000,"profit":false}] |
Income Taxes | (2.14M) | (994.00K) | 1.07M | 757.00K | 561.00K | [{"date":"2019-12-31","value":-200.19,"profit":false},{"date":"2020-12-31","value":-92.9,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":70.75,"profit":true},{"date":"2023-12-31","value":52.43,"profit":true}] |
Income After Taxes | (78.89M) | (118.34M) | (56.34M) | (96.33M) | (21.43M) | [{"date":"2019-12-31","value":-7888600000,"profit":false},{"date":"2020-12-31","value":-11834300000,"profit":false},{"date":"2021-12-31","value":-5634500000,"profit":false},{"date":"2022-12-31","value":-9632500000,"profit":false},{"date":"2023-12-31","value":-2142700000,"profit":false}] |
Income From Continuous Operations | (81.03M) | (119.34M) | (55.27M) | (95.57M) | (19.28M) | [{"date":"2019-12-31","value":-8102800000,"profit":false},{"date":"2020-12-31","value":-11933700000,"profit":false},{"date":"2021-12-31","value":-5527500000,"profit":false},{"date":"2022-12-31","value":-9556800000,"profit":false},{"date":"2023-12-31","value":-1928200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (78.89M) | (118.34M) | (56.34M) | (96.33M) | (21.43M) | [{"date":"2019-12-31","value":-7888600000,"profit":false},{"date":"2020-12-31","value":-11834300000,"profit":false},{"date":"2021-12-31","value":-5634500000,"profit":false},{"date":"2022-12-31","value":-9632500000,"profit":false},{"date":"2023-12-31","value":-2142700000,"profit":false}] |
EPS (Diluted) | (2.30) | (2.97) | (2.72) | (2.18) | (0.49) | [{"date":"2019-12-31","value":-230,"profit":false},{"date":"2020-12-31","value":-297,"profit":false},{"date":"2021-12-31","value":-272,"profit":false},{"date":"2022-12-31","value":-218,"profit":false},{"date":"2023-12-31","value":-49,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
YMAB | |
---|---|
Cash Ratio | 2.69 |
Current Ratio | 3.92 |
Quick Ratio | 3.54 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
YMAB | |
---|---|
ROA (LTM) | -11.98% |
ROE (LTM) | -24.78% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
YMAB | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.24 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.76 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
YMAB | |
---|---|
Trailing PE | NM |
Forward PE | 119.05 |
P/S (TTM) | 4.39 |
P/B | 4.01 |
Price/FCF | NM |
EV/R | 3.59 |
EV/Ebitda | NM |
Y mAbs Therapeutics (YMAB) share price today is $8.28
Yes, Indians can buy shares of Y mAbs Therapeutics (YMAB) on Vested. To buy Y mAbs Therapeutics from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in YMAB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Y mAbs Therapeutics (YMAB) via the Vested app. You can start investing in Y mAbs Therapeutics (YMAB) with a minimum investment of $1.
You can invest in shares of Y mAbs Therapeutics (YMAB) via Vested in three simple steps:
The 52-week high price of Y mAbs Therapeutics (YMAB) is $20.9. The 52-week low price of Y mAbs Therapeutics (YMAB) is $6.48.
The price-to-earnings (P/E) ratio of Y mAbs Therapeutics (YMAB) is
The price-to-book (P/B) ratio of Y mAbs Therapeutics (YMAB) is 4.01
The dividend yield of Y mAbs Therapeutics (YMAB) is 0.00%
The market capitalization of Y mAbs Therapeutics (YMAB) is $383.84M
The stock symbol (or ticker) of Y mAbs Therapeutics is YMAB